Tech Company Financing Transactions
PanTera Funding Round
EQT Life Sciences, Eurazeo and Korys participated in a $103 million Series A venture round for PanTera. The round was announced on 9/11/2024.
Transaction Overview
Company Name
Announced On
9/11/2024
Transaction Type
Venture Equity
Amount
$103,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to support the construction of a production facility in Belgium.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Boeretang 201
Mol, BE-2400
Belgium
Mol, BE-2400
Belgium
Phone
Undisclosed
Website
Email Address
Overview
PanTera wants to bring new hope to cancer patients by enabling the widespread application of radiopharmaceuticals for precision treatment of tumors. Our core belief is that these powerful medical tools deserve a central role in oncology for their potential to treat cancers effectively while preserving patient's quality of life. Our focus is on the radiotheranostics field, which facilitates patient-tailored optimization of treatment by tracking the distribution of therapeutic agents in the body. This cutting-edge approach minimizes patient side-effects while enhancing treatment efficacy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sven van den berghe
Chief Technical Officer
Samy Bertrand
VP - Bus. Development
Christophe Malice
Browse more venture capital transactions:
Prev: 9/11/2024: Connectly.ai venture capital transaction
Next: 9/11/2024: Aifleet venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs